Fig. 4: Evaluation of COVID-19 therapeutic drugs using BO-ALI.
From: Cell response analysis in SARS-CoV-2 infected bronchial organoids
a BO-ALI were infected with SARS-CoV-2 (1.3 × 105 TCID50/well) in the presence or absence of 10 μM camostat, 1 μM remdesivir, or 1 μM EIDD-2801 and then cultured with differentiation medium for 2 days. The amount of infectious virus in the supernatant was measured using the TCID50 assay. Statistical significance was evaluated using one-way ANOVA followed by Tukey’s post hoc test (*P < 0.05). b BO-ALI were infected with SARS-CoV-2 B, B.1, B.1.1.214, B.1.1.7, B.1.351, P.1, B.1.617.2, or B.1.1.529 (1.3 × 105 TCID50/well) and then cultured with differentiation medium. The virus copy number in the supernatant was measured by qPCR 1, 2, or 3 days after the infection. Data represent the mean ± SD from three independent experiments.
